Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 3/20 | 0.41 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2584682 | 0.87 | NFATC1 (0.41) | NFATC1GSK3BDYRK1AIKBKETBK1 | |
| SCHEMBL2583503 | 0.86 | NFATC1 (0.40) | NFATC1GSK3BDYRK1AIKBKETBK1 | |
| SCHEMBL2586015 | 0.83 | NFATC1 (0.38) | NFATC1GSK3BDYRK1AIKBKETBK1 | |
| SCHEMBL2587426 | 0.82 | GRIA1 (0.38) | NFATC1GSK3BDYRK1AIKBKETBK1 | |
| SCHEMBL2587408 | 0.79 | PDE10A (0.51) | GRIA1CACNG8 | |
| SCHEMBL2578378 | 0.74 | IKBKE (0.40) | NFATC1GSK3BDYRK1AIKBKETBK1 | |
| SCHEMBL2583465 | 0.74 | MAPK1 (0.46) | DYRK1AKDM5BKDM5A | |
| SCHEMBL2578159 | 0.73 | IKBKE (0.39) | NFATC1GSK3BDYRK1AIKBKETBK1 | |
| SCHEMBL2587373 | 0.71 | PDE2A (0.33) | — | |
| SCHEMBL2578262 | 0.71 | IKBKE (0.38) | NFATC1GSK3BDYRK1AIKBKETBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493889-B1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-06 | — | — | EP | disclosed |
| US-8716282-B2 | Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-06 | — | — | US | disclosed |
| US-20120220581-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN-CILAG, S.A. (ES) | 2012-08-30 | — | — | US | disclosed |
| US-20110269752-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | PASTOR-FERNANDEZ JOAQUIN | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220581-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | PDE12, PDE10A, PDE5A | USP1 1958/4885NFATC1 4373/4885GSK3B 1024/4885 |
| US-20110269752-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | PDE12, PDE10A, PDE5A | USP1 1958/4885NFATC1 4373/4885GSK3B 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.